Clinical Trial Update: Zuberitamab for EBV Infection Post-Allo-HSCT [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of Zuberitamab for Epstein-Barr virus infection after allogeneic hematopoietic stem cell transplantation; the study is not yet recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epstein-barr Virus Infection

Drugs mentioned

• Zuberitamab (Zuberitamab)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: HSCT, EBV Infection | Phase 2 | Status: NOT_YET_RECRUITING